vs
Apellis Pharmaceuticals, Inc.（APLS）与莱迪思半导体（LSCC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是莱迪思半导体的1.4倍（$199.9M vs $145.8M），莱迪思半导体净利率更高（-5.2% vs -29.5%，领先24.2%），莱迪思半导体同比增速更快（9.3% vs -5.9%），莱迪思半导体自由现金流更多（$44.0M vs $-14.3M），过去两年莱迪思半导体的营收复合增速更高（8.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
莱迪思半导体是美国专注于低功耗现场可编程门阵列（FPGA）设计制造的半导体企业，1983年成立，1989年上市，总部位于俄勒冈州希尔斯伯勒硅林区，在圣何塞、上海、马尼拉、槟城、新加坡等地设有运营网点，截至2022年员工超1000人，年营收超6.6亿美元。
APLS vs LSCC — 直观对比
营收规模更大
APLS
是对方的1.4倍
$145.8M
营收增速更快
LSCC
高出15.2%
-5.9%
净利率更高
LSCC
高出24.2%
-29.5%
自由现金流更多
LSCC
多$58.3M
$-14.3M
两年增速更快
LSCC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $145.8M |
| 净利润 | $-59.0M | $-7.6M |
| 毛利率 | — | 68.5% |
| 营业利润率 | -25.6% | 30.7% |
| 净利率 | -29.5% | -5.2% |
| 营收同比 | -5.9% | 9.3% |
| 净利润同比 | -62.2% | 14.6% |
| 每股收益（稀释后） | $-0.40 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLSCC
| Q1 26 | — | $145.8M | ||
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $133.3M | ||
| Q2 25 | $178.5M | $124.0M | ||
| Q1 25 | $166.8M | $120.2M | ||
| Q4 24 | $212.5M | $117.4M | ||
| Q3 24 | $196.8M | $127.1M | ||
| Q2 24 | $199.7M | $124.1M |
净利润APLSLSCC
| Q1 26 | — | $-7.6M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $2.8M | ||
| Q2 25 | $-42.2M | $2.9M | ||
| Q1 25 | $-92.2M | $5.0M | ||
| Q4 24 | $-36.4M | $16.5M | ||
| Q3 24 | $-57.4M | $7.2M | ||
| Q2 24 | $-37.7M | $22.6M |
毛利率APLSLSCC
| Q1 26 | — | 68.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 67.9% | ||
| Q2 25 | — | 68.4% | ||
| Q1 25 | — | 68.0% | ||
| Q4 24 | — | 61.1% | ||
| Q3 24 | — | 69.0% | ||
| Q2 24 | — | 68.3% |
营业利润率APLSLSCC
| Q1 26 | — | 0.7% | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -1.2% | ||
| Q2 25 | -18.6% | 3.8% | ||
| Q1 25 | -50.0% | 5.8% | ||
| Q4 24 | -12.3% | -10.4% | ||
| Q3 24 | -24.0% | 5.9% | ||
| Q2 24 | -14.7% | 18.2% |
净利率APLSLSCC
| Q1 26 | — | -5.2% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 2.1% | ||
| Q2 25 | -23.6% | 2.3% | ||
| Q1 25 | -55.3% | 4.2% | ||
| Q4 24 | -17.1% | 14.1% | ||
| Q3 24 | -29.2% | 5.7% | ||
| Q2 24 | -18.9% | 18.2% |
每股收益（稀释后）APLSLSCC
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.02 | ||
| Q2 25 | $-0.33 | $0.02 | ||
| Q1 25 | $-0.74 | $0.04 | ||
| Q4 24 | $-0.30 | $0.12 | ||
| Q3 24 | $-0.46 | $0.05 | ||
| Q2 24 | $-0.30 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $133.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $714.1M |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSLSCC
| Q1 26 | — | $133.9M | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $117.9M | ||
| Q2 25 | $370.0M | $107.2M | ||
| Q1 25 | $358.4M | $127.6M | ||
| Q4 24 | $411.3M | $136.3M | ||
| Q3 24 | $396.9M | $124.3M | ||
| Q2 24 | $360.1M | $109.2M |
股东权益APLSLSCC
| Q1 26 | — | $714.1M | ||
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $706.4M | ||
| Q2 25 | $156.3M | $687.0M | ||
| Q1 25 | $164.2M | $707.9M | ||
| Q4 24 | $228.5M | $710.9M | ||
| Q3 24 | $237.1M | $703.5M | ||
| Q2 24 | $264.3M | $698.8M |
总资产APLSLSCC
| Q1 26 | — | $883.1M | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $844.4M | ||
| Q2 25 | $821.4M | $808.6M | ||
| Q1 25 | $807.3M | $823.6M | ||
| Q4 24 | $885.1M | $843.9M | ||
| Q3 24 | $901.9M | $853.7M | ||
| Q2 24 | $904.5M | $827.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $44.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 30.2% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $153.3M |
8季度趋势，按日历期对齐
经营现金流APLSLSCC
| Q1 26 | — | $57.6M | ||
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $47.1M | ||
| Q2 25 | $4.4M | $38.5M | ||
| Q1 25 | $-53.4M | $31.9M | ||
| Q4 24 | $19.4M | $45.4M | ||
| Q3 24 | $34.1M | $44.0M | ||
| Q2 24 | $-8.3M | $21.9M |
自由现金流APLSLSCC
| Q1 26 | — | $44.0M | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $34.0M | ||
| Q2 25 | $4.4M | $31.3M | ||
| Q1 25 | $-53.4M | $23.3M | ||
| Q4 24 | $19.3M | $39.7M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | $-8.4M | $14.8M |
自由现金流率APLSLSCC
| Q1 26 | — | 30.2% | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 25.5% | ||
| Q2 25 | 2.5% | 25.2% | ||
| Q1 25 | -32.0% | 19.4% | ||
| Q4 24 | 9.1% | 33.8% | ||
| Q3 24 | — | 31.0% | ||
| Q2 24 | -4.2% | 11.9% |
资本支出强度APLSLSCC
| Q1 26 | — | 9.3% | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 9.8% | ||
| Q2 25 | 0.0% | 5.8% | ||
| Q1 25 | 0.0% | 7.2% | ||
| Q4 24 | 0.0% | 4.9% | ||
| Q3 24 | 0.0% | 3.7% | ||
| Q2 24 | 0.0% | 5.8% |
现金转化率APLSLSCC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 16.86× | ||
| Q2 25 | — | 13.23× | ||
| Q1 25 | — | 6.35× | ||
| Q4 24 | — | 2.75× | ||
| Q3 24 | — | 6.12× | ||
| Q2 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LSCC
暂无分部数据
